A Phase 1b clinical trial of PAC-1 for glioblastoma patients has begun

A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain. This phase Ib trial will determine if the experimental drug PAC-1 can be used safely in combination with a standard […]

PAC-1 shows efficacy in dog trial

Chasing cancer with dogs — Treating canine cancers is helping researchers learn more about human forms of the disease. Thunder is a middle-aged mutt with a cheery disposition. He is slim, with a black coat and white patches on his belly and toes. His owner, Jeanneen Terry from Chicago, is unsure of Thunder’s pedigree. “He could […]

Vanquish Oncology, Inc. announces multimillion dollar investment to move PAC-1 to human clinical trials for cancer patients.

Cancer drug tested in pet dogs is now bound for human trials. University of Illinois chemistry professor Paul Hergenrother, left, and veterinary clinical medicine professor Tim Fan led a study of an anti-cancer compound in pet dogs that is now headed for human clinical trials. Continue reading the Illinois News Bureau article.